Previous 10 | Next 10 |
NEW YORK , Nov. 19, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, conducted an investor event and conference call yesterday, November 18, 2...
NEW YORK , Nov. 14, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, will hold an investor event and conference call to review the positive results from...
Solid Biosciences (NASDAQ: SLDB ) -71% on another clinical hold on DMD gene therapy . More news on: Solid Biosciences Inc., Diplomat Pharmacy, Inc., Fluent, Inc., Stocks on the move, Read more ...
NEW YORK , November 12, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced positive results from the initial cohort of the Phase IIb trial evaluatin...
Market Assessment Oramed Pharmaceuticals ( ORMP ) is an Israeli small-cap ($54M) biopharma developing orally ingestible therapeutics for type 2 diabetes and weight management. ORMD-0801 is the lead and a Phase 2b investigative oral insulin capsule in clinical evaluation for type 2 diabet...
NEW YORK , Sept. 18, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that the company's Chief Executive Officer, Nad...
NEW YORK , Sept. 17, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the treatment of the last patient in the primary cohort of the Ph...
Oramed Pharmaceuticals (NASDAQ: ORMP ) initiated with Buy rating and $7 (136% upside) at Ladenburg Thalmann. Shares up 3% premarket. More news on: Oramed Pharmaceuticals Inc., PhaseBio Pharmaceuticals, Inc., Bicycle Therapeutics plc, Healthcare stocks news, Stocks on the move, ...
NEW YORK , Sept. 3, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that the company will present at three confere...
Insider buying was lackluster last week with insiders purchasing just $10.39 million of stock last week compared to $54.38 million in the week prior. This is the fourth week in a row we have seen a decline in insider buying and coincides with the earnings related quiet period. We should see a ...
News, Short Squeeze, Breakout and More Instantly...
Oramed Pharmaceuticals Inc. Company Name:
ORMP Stock Symbol:
NASDAQ Market:
Oramed Pharmaceuticals Inc. Website:
PALO ALTO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today...
Crescent Energy Company Class A (CRGY) is expected to report $0.21 for Q4 2023 ThredUp Inc. (TDUP) is expected to report $-0.13 for Q4 2023 Wright Investors` Service Holdings Inc (IWSH) is expected to report for Q4 2023 Bridgford Foods Corporation (BRID) is expected to report for Q1 2...